See more : Synnex (Thailand) Public Company Limited (SYNEX-R.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shenzhen Kangtai Biological Products Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Medicalsystem Biotechnology Co., Ltd. (300439.SZ) Income Statement Analysis – Financial Results
- Xstate Resources Limited (XST.AX) Income Statement Analysis – Financial Results
- TrustBIX Inc. (TBIX.V) Income Statement Analysis – Financial Results
- Valvoline Inc. (VVV) Income Statement Analysis – Financial Results
- Stampede Capital Limited (SCAPDVR.NS) Income Statement Analysis – Financial Results
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.biokangtai.com
About Shenzhen Kangtai Biological Products Co., Ltd.
Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined with live attenuated vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, and HIB conjugate vaccine. It has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.48B | 3.16B | 3.65B | 2.26B | 1.94B | 2.02B | 1.16B | 551.94M | 452.74M | 303.36M | 250.51M | 122.50M |
| Cost of Revenue | 655.29M | 499.95M | 986.43M | 226.31M | 163.67M | 179.41M | 136.33M | 118.29M | 165.46M | 96.61M | 77.92M | 30.16M |
| Gross Profit | 2.82B | 2.66B | 2.67B | 2.03B | 1.78B | 1.84B | 1.02B | 433.65M | 287.28M | 206.76M | 172.59M | 92.34M |
| Gross Profit Ratio | 81.16% | 84.17% | 72.99% | 89.99% | 91.58% | 91.10% | 88.26% | 78.57% | 63.45% | 68.16% | 68.90% | 75.38% |
| Research & Development | 500.75M | 801.86M | 354.26M | 267.06M | 198.26M | 177.82M | 84.74M | 39.53M | 48.26M | 45.75M | 36.46M | 18.99M |
| General & Administrative | 62.88M | 58.20M | 65.51M | 35.43M | 31.48M | 41.26M | 35.70M | 24.40M | 17.39M | 18.34M | 28.48M | 55.60M |
| Selling & Marketing | 1.19B | 1.09B | 578.24M | 878.41M | 784.57M | 1.01B | 615.42M | 219.74M | 102.82M | 40.86M | 57.10M | 50.78M |
| SG&A | 1.52B | 1.14B | 643.75M | 913.84M | 816.05M | 1.05B | 651.12M | 244.13M | 120.21M | 59.21M | 85.58M | 106.38M |
| Other Expenses | -118.79M | 74.41M | 73.93M | 110.47M | 92.98M | 7.83M | -4.18M | 13.62M | 2.30M | -1.37M | 34.01M | 42.79M |
| Operating Expenses | 1.87B | 2.02B | 1.07B | 1.29B | 1.11B | 1.33B | 759.52M | 324.56M | 207.95M | 144.42M | 159.73M | 107.59M |
| Cost & Expenses | 2.53B | 2.52B | 2.06B | 1.52B | 1.27B | 1.50B | 895.85M | 442.85M | 373.41M | 241.03M | 237.65M | 137.75M |
| Interest Income | 115.62M | 132.62M | 114.91M | 24.06M | 3.52M | 6.59M | 465.55K | 352.52K | 1.62M | 767.74K | 369.54K | 7.82M |
| Interest Expense | 113.71M | 108.97M | 54.51M | 2.34M | 8.93M | 23.93M | 2.17M | 2.09M | 9.05M | 20.31M | 15.61M | 0.00 |
| Depreciation & Amortization | 240.72M | 229.04M | 433.06M | 106.50M | 84.29M | 58.69M | 60.90M | 47.92M | 50.25M | 48.87M | 48.42M | 32.73M |
| EBITDA | 1.30B | 442.97K | 1.90B | 881.55M | 756.76M | 572.24M | 301.34M | 150.88M | 124.21M | 103.65M | 66.93M | 17.48M |
| EBITDA Ratio | 37.24% | 30.02% | 58.29% | 38.52% | 39.70% | 29.27% | 27.65% | 30.71% | 30.07% | 36.89% | 38.21% | 18.47% |
| Operating Income | 948.92M | 747.03M | 1.45B | 775.37M | 657.82M | 481.26M | 242.16M | 85.68M | 69.16M | 35.98M | -33.97M | -28.27M |
| Operating Income Ratio | 27.29% | 23.66% | 39.76% | 34.29% | 33.85% | 23.86% | 20.85% | 15.52% | 15.28% | 11.86% | -13.56% | -23.08% |
| Total Other Income/Expenses | -8.60M | -1.09B | -13.00M | -2.96M | 5.63M | 7.83M | -4.18M | 13.30M | 1.93M | -1.51M | 33.89M | 42.79M |
| Income Before Tax | 940.32M | -338.25M | 1.44B | 772.41M | 663.45M | 489.09M | 237.98M | 98.98M | 71.09M | 34.47M | -78.43K | 14.51M |
| Income Before Tax Ratio | 27.04% | -10.71% | 39.41% | 34.16% | 34.14% | 24.25% | 20.50% | 17.93% | 15.70% | 11.36% | -0.03% | 11.85% |
| Income Tax Expense | 79.02M | -205.54M | 175.87M | 93.22M | 88.94M | 53.40M | 23.28M | 12.77M | 8.27M | 3.31M | -1.59M | 3.07M |
| Net Income | 861.30M | -132.71M | 1.26B | 679.19M | 574.51M | 435.69M | 214.70M | 86.21M | 62.82M | 31.16M | 1.51M | 11.45M |
| Net Income Ratio | 24.77% | -4.20% | 34.59% | 30.04% | 29.56% | 21.60% | 18.49% | 15.62% | 13.88% | 10.27% | 0.60% | 9.35% |
| EPS | 0.77 | -0.12 | 1.16 | 0.64 | 0.57 | 0.44 | 0.22 | 0.10 | 0.07 | 0.04 | 0.00 | 0.01 |
| EPS Diluted | 0.77 | -0.12 | 1.14 | 0.63 | 0.56 | 0.44 | 0.22 | 0.10 | 0.07 | 0.04 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 1.12B | 1.11B | 1.09B | 1.06B | 1.01B | 995.85M | 981.28M | 898.06M | 884.81M | 828.79M | 888.57M | 914.28M |
| Weighted Avg Shares Out (Dil) | 1.12B | 1.11B | 1.11B | 1.08B | 1.02B | 995.85M | 981.50M | 898.09M | 885.39M | 829.59M | 904.81M | 914.28M |
Source: https://incomestatements.info
Category: Stock Reports